Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
57 hedge funds and large institutions have $422M invested in Akero Therapeutics in 2019 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 24 increasing their positions, 12 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 12
46% more capital invested
Capital invested by funds: $288M → $422M (+$133M)
21.91% more ownership
Funds ownership: 44.62% → 66.53% (+22%)
6% more funds holding
Funds holding: 54 → 57 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$7.85M |
| 2 |
BlackRock
New York
|
+$4.8M |
| 3 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$2.93M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.47M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.96M |
| 2 |
Millennium Management
New York
|
-$1.67M |
| 3 |
Alkeon Capital Management
New York
|
-$1.31M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.14M |
| 5 |
HSBC Holdings
London,
United Kingdom
|
-$615K |
AKRO Hedge Fund Activity: Q4 2019 in Review
57 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q4 2019, worth a combined $422M — up 46% from $288M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new AKRO positions and 3 closed out — a net gain of 8 holders — while 24 added to existing stakes and 12 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $7.85M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $2.96M sold.
- 57 institutional investors held Akero Therapeutics (AKRO) as of Q4 2019, up from 54 in Q3 2019.
- Funds reported $422M of Akero Therapeutics stock for Q4 2019, up 46% quarter-over-quarter.
- 11 funds opened new Akero Therapeutics positions in Q4 2019 and 3 closed out, a net change of +8 holders.
- The largest Akero Therapeutics buyer in Q4 2019 was Janus Henderson Group, an estimated $7.85M added.
- The largest Akero Therapeutics seller in Q4 2019 was Sphera Funds Management, an estimated $2.96M sold.
Based on aggregated 13F filings for Q4 2019.